News for Corcept Therapeutics Incorporated (0I3Q.L)

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeu

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate upd

In our monthly Rare Stock Picks series, we're highlighting January 2025 investment picks. Click here for the list of January 2025 Buy recommendations.

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Corcept Therapeutics stock soars to all-time high of $62.34

We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts.

We recently compiled a list of the 15 Best Growth Stocks to Buy for the Next 5 Years. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against...

Kevin Mahn, President & CIO at Hennion & Walsh Asset Management, recently appeared on CNBC on January 6 to discuss the current market momentum and emphasize the need for investors to be selective in 2025...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against the ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

BlackRock Advantage Small Cap Growth Fund posted returns of 8.96% (I) for the third quarter of 2024. Click here to read the full commentary.

Loading... Loading... Shares of Applied DNA Sciences, Inc. APDN fell sharply during Tuesday's session after the company announced the pricing of a $12 million ...